🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Recruitingn/aAges 18 Years - anyMaleUniversity of Michigan Rogel Cancer Center
NCT07096999 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * \* 177Lu-617 PSMA treatment scheduled for mCRPC * Clinically stable as determined by the nuclear medicine clinicians * Male * ≥ 18 years of age * Willing and able to provide informed consent Exclusion Criteria: * Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
💊

What it tests

  • Non-Interventional Study
📍

Where

1 site
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy